Mesa Laboratories Stock Today
| MLAB Stock | USD 124.24 1.88 1.49% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Mesa Laboratories is trading at 124.24 as of the 20th of March 2025, a 1.49 percent decrease since the beginning of the trading day. The stock's open price was 126.12. Mesa Laboratories has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of January 1995 | Category Technology | Classification Health Care |
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado. The company has 5.43 M outstanding shares of which 191.67 K shares are now shorted by private and institutional investors with about 5.79 trading days to cover. More on Mesa Laboratories
Moving together with Mesa Stock
Moving against Mesa Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mesa Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| COO, Vice President | Gary Owens | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Measuring and Control Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Composite Total, Measuring and Control Equipment, Health Care, Life Sciences Tools & Services, Scientific & Technical Instruments, Technology (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMesa Laboratories can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mesa Laboratories' financial leverage. It provides some insight into what part of Mesa Laboratories' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mesa Laboratories (MLAB) is traded on NASDAQ Exchange in USA. It is located in 12100 West Sixth Avenue, Lakewood, CO, United States, 80228 and employs 736 people. Mesa Laboratories is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 685.29 M. Mesa Laboratories conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 5.43 M outstanding shares of which 191.67 K shares are now shorted by private and institutional investors with about 5.79 trading days to cover.
Mesa Laboratories currently holds about 43.75 M in cash with 44.13 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.23.
Check Mesa Laboratories Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Mesa Laboratories is $685.29 Million. The majority of Mesa Laboratories outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mesa Laboratories to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mesa Laboratories. Please pay attention to any change in the institutional holdings of Mesa Laboratories as this could imply that something significant has changed or is about to change at the company. Also note that almost seventy-seven thousand one hundred fifty-seven invesors are currently shorting Mesa Laboratories expressing very little confidence in its future performance.
Check Mesa Ownership Details
Mesa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 124.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 113.8 K | |
| Northern Trust Corp | 2024-12-31 | 93.8 K | |
| Hhg Plc | 2024-12-31 | 86.3 K | |
| Raymond James & Associates | 2024-09-30 | 76.9 K | |
| Kennedy Capital Management Inc | 2024-12-31 | 74.6 K | |
| Bank Of America Corp | 2024-12-31 | 68.5 K | |
| Acadian Asset Management Llc | 2024-12-31 | 68.1 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 62.6 K | |
| Blackrock Inc | 2024-12-31 | 844.4 K | |
| Conestoga Capital Advisors, Llc | 2024-12-31 | 573 K |
Mesa Laboratories Historical Income Statement
Mesa Stock Against Markets
Mesa Laboratories Corporate Management
| Peter Dansky | Pres Genomics | Profile | |
| Brian Archbold | Senior Improvement | Profile | |
| Bryan Leo | VP Operations | Profile | |
| Garrett Krushefski | VP Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesa Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesa Laboratories. If investors know Mesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesa Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.875 | Dividend Share 0.64 | Earnings Share (46.32) | Revenue Per Share | Quarterly Revenue Growth 0.175 |
The market value of Mesa Laboratories is measured differently than its book value, which is the value of Mesa that is recorded on the company's balance sheet. Investors also form their own opinion of Mesa Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Mesa Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesa Laboratories' market value can be influenced by many factors that don't directly affect Mesa Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesa Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesa Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesa Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.